STOCK TITAN

Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced that it will report its first quarter 2022 financial results on May 5, 2022, at 8:30 a.m. ET. The company's management will host a conference call to discuss the results and company updates. Karyopharm is recognized for its pioneering work in cancer therapies, particularly with its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company continues to expand its presence in international markets, including Europe and Asia.

Positive
  • Karyopharm's XPOVIO® is approved in the U.S. for three oncology indications.
  • The company is expanding regulatory approvals in international markets.
Negative
  • None.

-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET --

NEWTON, Mass., April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®), China and Singapore. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision View original content:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2022-financial-results-on-may-5-2022-301534780.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm report its first quarter 2022 financial results?

Karyopharm will report its first quarter 2022 financial results on May 5, 2022.

What is the time for Karyopharm's conference call?

The conference call is scheduled for 8:30 a.m. ET on May 5, 2022.

What is Karyopharm's lead product for cancer treatment?

Karyopharm's lead product is XPOVIO® (selinexor), an oral exportin 1 inhibitor.

In which markets is Karyopharm expanding its product approvals?

Karyopharm is expanding its product approvals in Europe, China, and Singapore.

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

79.84M
118.24M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON